GlobeImmune (Louisville, CO) a clinical-stage company focused on developing targeted immunogens for the treatment of cancer and infectious diseases, has had an abstract (“GI-5005 Therapeutic Vaccine Plus PEG-IFN/Ribavirin Improves End of Treatment Response at 48 Weeks Versus PEG-IFN/Ribavirin in Naïve Genotype 1 Chronic HCV Patients”) for their investigational hepatitis C virus product candidate accepted for [...]

• 452http://clsdf.com/2009/10/globeimmune-presenting-phase-ii-data-aasld/GlobeImmune+%7C+Presenting+Phase+II+Data+%40+AASLD2009-10-06+14%3A10%3A00admin

Biodesix (Broomfiled, CO) a commercial-stage molecular diagnostics company focused on proteomic-based diagnostics, closed the first tranche of a $10M Series B financing. The company is enabling personalized health care via their mass spectrometry-based molecular profiling proprietary platform technology, ProTS®, to discover and validate diagnostic tests for the improvement of patient outcomes. Biodesix’ first product, VeriStrat®, [...]

• 451http://clsdf.com/2009/10/biodesix-first-tranche-of-10m-series-b/Biodesix+%7C+First+Tranche+of+%2410M+Series+B2009-10-06+13%3A41%3A00admin